Application of urine proteomics for biomarker discovery in drug-induced liver injury

References

• Abdelmegeed MA, Jang S, Banerjee A, Hardwick JP, Song BJ. (2013). Robust protein nitration contributes to acetaminophen-induced mitochondrial dysfunction and acute liver injury. Free Radic Biol Med, 60, 211–22.
   PubMed Web of Science ®Google Scholar
• Abdelmegeed MA, Moon KH, Chen C, Gonzalez FJ, Song BJ. (2010). Role of cytochrome P450 2E1 in protein nitration and ubiquitin-mediated degradation during acetaminophen toxicity. Biochem Pharmacol, 79, 57–66.
   PubMed Web of Science ®Google Scholar
• Actis GC, Debernardi-Venon W, Lagget M, Marzano A, Ottobrelli A, Ponzetto A, ET Al. (1995). Hepatotoxicity of intravenous cyclosporin A in patients with acute ulcerative colitis on total parenteral nutrition. Liver, 15, 320–3.
   PubMedGoogle Scholar
• Adams DH, Ju C, Ramaiah SK, Uetrecht J, Jaeschke H. (2010). Mechanisms of immune-mediated liver injury. Toxicol Sci, 115, 307–21.
   PubMed Web of Science ®Google Scholar
• Adler M, Hoffmann D, Ellinger-Ziegelbauer H, Hewitt P, Matheis K, Mulrane L, et al. (2010). Assessment of candidate biomarkers of drug-induced hepatobiliary injury in preclinical toxicity studies. Toxicol Lett, 196, 1–11.
   PubMed Web of Science ®Google Scholar
• Ahbeddou N, Belbaraka R, Fetohi M, Errihani H. (2011). Tamoxifen-induced hepatotoxicity. Indian J Cancer, 48, 385.
   PubMedGoogle Scholar
• Akbal E, Koklu S, Kocak E, Cakal B, Gunes F, Basar O, et al. (2013). Liver fatty acid-binding protein is a diagnostic marker to detect liver injury due to chronic hepatitis C infection. Arch Med Res, 44, 34–8.
   PubMedGoogle Scholar
• Alam I, Ferrell LD, Bass NM. (1996). Vanishing bile duct syndrome temporally associated with ibuprofen use. Am J Gastroenterol, 91, 1626–30.
   PubMed Web of Science ®Google Scholar
• Altuntas Y, Ozturk B, Erdem L, Gunes G, Karul S, Ucak S, Sengul A. (2003). Phenytoin-induced toxic cholestatic hepatitis in a patient with skin lesions: case report. South Med J, 96, 201–3.
   PubMed Web of Science ®Google Scholar
• Amacher DE. (1998). Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul Toxicol Pharmacol, 27, 119–30.
   PubMedGoogle Scholar
• Amacher DE. (2012). The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury. Expert Opin Drug Metab Toxicol, 8, 335–47.
   PubMed Web of Science ®Google Scholar
• Ames DJ, Bhathal PS, Davies BM, Fraser JR, Gibson PR, Roberts S. (1990). Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine. Aust N Z J Med, 20, 193–5.
   PubMedGoogle Scholar
• Andrade RJ, Lucena MI, Fernandez MC, Gonzalez M. (2000). Fatal hepatitis associated with nimesulide. J Hepatol, 32, 174.
   PubMedGoogle Scholar
• Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. (2005). Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology, 129, 512–21.
   PubMed Web of Science ®Google Scholar
• Antoine DJ, Jenkins RE, Dear JW, Williams DP, Mcgill MR, Sharpe MR, et al. (2012). Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol, 56, 1070–9.
   PubMed Web of Science ®Google Scholar
• Au JS, Navarro VJ, Rossi S. (2011). Review article: Drug-induced liver injury–its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther, 34, 11–20.
   PubMed Web of Science ®Google Scholar
• Balaguer F, Fernandez J, Lozano M, Miquel R, Mas A. (2005). Cocaine-induced acute hepatitis and thrombotic microangiopathy. JAMA, 293, 797–8.
   PubMedGoogle Scholar
• Banerjee AK, Lakhani S, Vincent M, Selby P. (1988). Dose-dependent acute hepatitis associated with administration of high dose methotrexate. Hum Toxicol, 7, 561–2.
   PubMedGoogle Scholar
• Banks AT, Zimmerman HJ, Ishak KG, Harter JG. (1995). Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology, 22, 820–7.
   PubMed Web of Science ®Google Scholar
• Banon-Maneus E, Diekmann F, Carrascal M, Quintana LF, Moya-Rull D, Bescos M, et al. (2010). Two-dimensional difference gel electrophoresis urinary proteomic profile in the search of nonimmune chronic allograft dysfunction biomarkers. Transplantation, 89, 548–58.
   PubMedGoogle Scholar
• Bartolone JB, Beierschmitt WP, Birge RB, Hart SG, Wyand S, Cohen SD, Khairallah EA. (1989). Selective acetaminophen metabolite binding to hepatic and extrahepatic proteins: an in vivo and in vitro analysis. Toxicol Appl Pharmacol, 99, 240–9.
   PubMed Web of Science ®Google Scholar
• Belinsky GS, Parke AL, Huang Q, Blanchard K, Jayadev S, Stoll R, et al. (2007). The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci, 97, 582–94.
   PubMed Web of Science ®Google Scholar
• Belknap MK, Mcclelland KJ. (1993). Cholestatic hepatitis associated with amoxicillin-clavulanate. Wis Med J, 92, 241–2.
   PubMedGoogle Scholar
• Bell LN, Vuppalanchi R, Watkins PB, Bonkovsky HL, Serrano J, Fontana RJ, et al. (2012). Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther, 35, 600–12.
   PubMed Web of Science ®Google Scholar
• Benjamin SB, Goodman ZD, Ishak KG, Zimmerman HJ, Irey NS. (1985). The morphologic spectrum of halothane-induced hepatic injury: analysis of 77 cases. Hepatology, 5, 1163–71.
   PubMedGoogle Scholar
• Bennett WE Jr, Turmelle YP, Shepherd RW. (2009). Ibuprofen- induced liver injury in an adolescent athlete. Clin Pediatr (Phila), 48, 84–6.
   PubMedGoogle Scholar
• Benson GD, Anderson PK, Combes B, Ishak KG. (1988). Prolonged jaundice following ketoconazole-induced hepatic injury. Dig Dis Sci, 33, 240–6.
   PubMed Web of Science ®Google Scholar
• Bercoff E, Bernuau J, Degott C, Kalis B, Lemaire A, Tilly H, et al. (1985). Ketoconazole-induced fulminant hepatitis. Gut, 26, 636–8.
   PubMed Web of Science ®Google Scholar
• Bhogaraju A, Nazeer S, Al-Baghdadi Y, Rahman M, Wrestler F, Patel N. (1999). Diclofenac-associated hepatitis. South Med J, 92, 711–3.
   PubMedGoogle Scholar
• Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. (1975). Isoniazid-associated hepatitis in 114 patients. Gastroenterology, 69, 289–302.
   PubMed Web of Science ®Google Scholar
• Blackburn AM, Amiel SA, Millis RR, Rubens RD. (1984). Tamoxifen and liver damage. Br Med J (Clin Res Ed), 289, 288.
   PubMed Web of Science ®Google Scholar
• Boelsterli UA. (2003). Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol, 192, 307–22.
   PubMed Web of Science ®Google Scholar
• Boelsterli UA, Hsiao CJ. (2008). The heterozygous Sod2(+/+) mouse: modeling the mitochondrial role in drug toxicity. Drug Discov Today, 13, 982–8.
   PubMed Web of Science ®Google Scholar
• Boffa MJ, Smith A, Chalmers RJ, Mitchell DM, Rowan B, Warnes TW, et al. (1996). Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol, 135, 538–44.
   PubMed Web of Science ®Google Scholar
• Booth AM, Caldwell SH, Iezzoni JC. (2000). Troglitazone-associated hepatic failure. Am J Gastroenterol, 95, 557–8.
   PubMed Web of Science ®Google Scholar
• Borlak J, Chatterji B, Londhe KB, Watkins PB. (2013). Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury. Genome Med, 5, 86.
   PubMedGoogle Scholar
• Breen EG, Mcnicholl J, Cosgrove E, Mccabe J, Stevens FM. (1986). Fatal hepatitis associated with diclofenac. Gut, 27, 1390–3.
   PubMed Web of Science ®Google Scholar
• Breuskin F, Horsmans Y, Rahier J, Lambert M. (2001). Recurrent immuno-allergic hepatitis related to amoxicillin-clavulanic acid. Acta Clin Belg, 56, 255–7.
   PubMed Web of Science ®Google Scholar
• Cai Q, Bensen M, Greene R, Kirchner J. (2000). Tamoxifen-induced transient multifocal hepatic fatty infiltration. Am J Gastroenterol, 95, 277–9.
   PubMed Web of Science ®Google Scholar
• Canas B, Lopez-Ferrer D, Ramos-Fernandez A, Camafeita E, Calvo E. (2006). Mass spectrometry technologies for proteomics. Brief Funct Genomic Proteomic, 4, 295–320.
   PubMedGoogle Scholar
• Carey EJ, Vargas HE, Douglas DD, Balan V, Byrne TJ, Harrison ME, Rakela J. (2008). Inpatient admissions for drug-induced liver injury: results from a single center. Dig Dis Sci, 53, 1977–82.
   PubMed Web of Science ®Google Scholar
• Carro JA, Senior J, Rubio CE, Torres EA. (1989). Phenytoin induced fatal hepatic injury. Bol Asoc Med P R, 81, 359–60.
   PubMedGoogle Scholar
• Chaabane NB, Safer L, Njim L, Zakhama A, Saffar H. (2011). Cholestatic hepatitis related to amoxicillin. Drug Chem Toxicol, 34, 357–8.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Bjornsson E. (2010). Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology, 138, 2246–59.
   PubMed Web of Science ®Google Scholar
• Chamouard P, Walter P, Baumann R, Poupon R. (2005). Prolonged cholestasis associated with short-term use of celecoxib. Gastroenterol Clin Biol, 29, 1286–8.
   PubMedGoogle Scholar
• Chandramouli K, Qian PY. (2009). Proteomics: challenges, techniques and possibilities to overcome biological sample complexity. Hum Genomics Proteomics 2009, doi:10.4061/2009/239204.
   PubMedGoogle Scholar
• Chen X, Ma SW, Ma XM, Xu YJ, Tang NJ. (2012). Changes in fibrinopeptide A peptides in the sera of rats chronically exposed to low doses of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Environ Toxicol Pharmacol, 33, 191–6.
   PubMed Web of Science ®Google Scholar
• Cheng L, You Q, Yin H, Holt MP, Ju C. (2010). Involvement of natural killer T cells in halothane-induced liver injury in mice. Biochem Pharmacol, 80, 255–61.
   PubMed Web of Science ®Google Scholar
• Chien RN, Sheen IS, Liaw YF. (2003). Unintentional rechallenge resulting in a causative relationship between ketoconazole and acute liver injury. Int J Clin Pract, 57, 829–30.
   PubMedGoogle Scholar
• Chitturi S, Farrell GC. (2001). Drug-induced cholestasis. Semin Gastrointest Dis, 12, 113–24.
   PubMedGoogle Scholar
• Cho IJ, Kim YW, Han CY, Kim EH, Anderson RA, Lee YS, et al. (2010). E-cadherin antagonizes transforming growth factor beta1 gene induction in hepatic stellate cells by inhibiting RhoA-dependent Smad3 phosphorylation. Hepatology, 52, 2053–64.
   PubMed Web of Science ®Google Scholar
• Clegg DO, Furst DE, Tolman KG, Pogue R. (1989). Acute, reversible hepatic failure associated with methotrexate treatment of rheumatoid arthritis. J Rheumatol, 16, 1123–6.
   PubMedGoogle Scholar
• Colletti RB, Trainer TD, Krawisz BR. (1986). Reversible valproate fulminant hepatic failure. J Pediatr Gastroenterol Nutr, 5, 990–4.
   PubMedGoogle Scholar
• Cosgrove BD, King BM, Hasan MA, Alexopoulos LG, Farazi PA, Hendriks BS, et al. (2009). Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol, 237, 317–30.
   PubMed Web of Science ®Google Scholar
• Cundiff J, Joe S. (2007). Amoxicillin-clavulanic acid-induced hepatitis. Am J Otolaryngol, 28, 28–30.
   PubMed Web of Science ®Google Scholar
• Daly AK. (2010). Drug-induced liver injury: past, present and future. Pharmacogenomics, 11, 607–11.
   PubMed Web of Science ®Google Scholar
• Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. (2007). Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology, 132, 272–81.
   PubMed Web of Science ®Google Scholar
• Danielides IC, Constantoulakis M, Daikos GK. (1983). Hepatitis on high dose isoniazid: reintroduction of the drug in severe tuberculous meningitis. Am J Gastroenterol, 78, 378–80.
   PubMedGoogle Scholar
• David S, Hamilton JP. (2010). Drug-induced Liver Injury. US Gastroenterol Hepatol Rev, 6, 73–80.
   PubMedGoogle Scholar
• Decramer S, Gonzalez De Peredo A, Breuil B, Mischak H, Monsarrat B, Bascands JL, Schanstra JP. (2008). Urine in clinical proteomics. Mol Cell Proteomics, 7, 1850–62.
   PubMed Web of Science ®Google Scholar
• Di Mizio G, Gambardella A, Labate A, Perna A, Ricci P, Quattrone A. (2007). Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients. Seizure, 16, 653–6.
   PubMed Web of Science ®Google Scholar
• Duarte PA, Chow CC, Simmons F, Ruskin J. (1984). Fatal hepatitis associated with ketoconazole therapy. Arch Intern Med, 144, 1069–70.
   PubMedGoogle Scholar
• Dunk AA, Walt RP, Jenkins WJ, Sherlock SS. (1982). Diclofenac hepatitis. Br Med J (Clin Res Ed), 284, 1605–6.
   PubMed Web of Science ®Google Scholar
• Dunn JM, McNair A. (2007). Prolonged cholestasis following successful removal of common bile duct stones: beware patients on estrogen therapy. World J Gastroenterol, 13, 6277–80.
   PubMedGoogle Scholar
• El-Sherbiny GA, Taye A, Abdel-Raheem IT. (2009). Role of ursodeoxycholic acid in prevention of hepatotoxicity caused by amoxicillin-clavulanic acid in rats. Ann Hepatol, 8, 134–40.
   PubMedGoogle Scholar
• El H II, Malik SM, Alwakeel HR, Shaikh OS, Sasatomi E, Kandil HM. (2009). Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation. World J Gastroenterol, 15, 3937–9.
   PubMedGoogle Scholar
• Elouni B, Ben Salem C, Zamy M, Ganne N, Beaugrand M, Bouraoui K, Biour M. (2010). Cytolytic hepatitis possibly related to levonorgestrel/ethinylestradiol oral contraceptive use: 2 case reports. Ann Pharmacother, 44, 2035–7.
   PubMed Web of Science ®Google Scholar
• elSisi AE, Earnest DL, Sipes IG. (1993a). Vitamin A potentiation of carbon tetrachloride hepatotoxicity: enhanced lipid peroxidation without enhanced biotransformation. Toxicol Appl Pharmacol, 119, 289–94.
   PubMedGoogle Scholar
• elSisi AE, Earnest DL, Sipes IG. (1993b). Vitamin A potentiation of carbon tetrachloride hepatotoxicity: role of liver macrophages and active oxygen species. Toxicol Appl Pharmacol, 119, 295–301.
   PubMed Web of Science ®Google Scholar
• Endo S, Toyoda Y, Fukami T, Nakajima M, Yokoi T. (2012). Stimulation of human monocytic THP-1 cells by metabolic activation of hepatotoxic drugs. Drug Metab Pharmacokinet, 27, 621–30.
   PubMed Web of Science ®Google Scholar
• Ersoz G, Karasu Z, Yildiz C, Akarca US, Yuce G, Batur Y. (2001). Severe toxic hepatitis associated with amoxycillin and clavulanic acid. J Clin Pharm Ther, 26, 225–9.
   PubMed Web of Science ®Google Scholar
• Etxagibel A, Julia MR, Brotons A, Company MM, Dolz C. (2008). Drug-induced hepatitis superimposed on the presence of anti-SLA antibody: a case report. J Med Case Rep, 2, 25.
   PubMedGoogle Scholar
• Fiedler GM, Baumann S, Leichtle A, Oltmann A, Kase J, Thiery J, Ceglarek U. (2007). Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem, 53, 421–8.
   PubMed Web of Science ®Google Scholar
• Findor JA, Sorda JA, Igartua EB, Avagnina A. (1998). Ketoconazole-induced liver damage. Medicina (B Aires), 58, 277–81.
   PubMedGoogle Scholar
• Fontana RJ. (2010). Approaches to the study of drug-induced liver injury. Clin Pharmacol Ther, 88, 416–9.
   PubMedGoogle Scholar
• Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, et al. (2014). Idiosyncratic drug induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology, doi:10.1053/j.gastro.2014.03.045.
   Google Scholar
• Fontana RJ, Mccashland TM, Benner KG, Appelman HD, Gunartanam NT, Wisecarver JL, et al. (1999). Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. Liver Transpl Surg, 5, 480–4.
   PubMedGoogle Scholar
• Fredriksson L, Herpers B, Benedetti G, Matadin Q, Puigvert JC, De Bont H., et al. (2011). Diclofenac inhibits tumor necrosis factor-alpha-induced nuclear factor-kappaB activation causing synergistic hepatocyte apoptosis. Hepatology, 53, 2027–41.
   PubMed Web of Science ®Google Scholar
• Fujii T, Fuchs BC, Yamada S, Lauwers GY, Kulu Y, Goodwin JM, et al. (2010). Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor. BMC Gastroenterol, 10, 79.
   PubMed Web of Science ®Google Scholar
• Fukano M, Amano S, Sato J, Yamamoto K, Adachi H, Okabe H, et al. (2000). Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination. Hum Pathol, 31, 250–3.
   PubMed Web of Science ®Google Scholar
• Galan MV, Gordon SC, Silverman AL. (2001). Celecoxib-induced cholestatic hepatitis. Ann Intern Med, 134, 254.
   PubMed Web of Science ®Google Scholar
• Galeone D, Lamontanara G, Torelli D. (1985). Acute hepatitis in a patient treated with carbamazepine. J Neurol, 232, 301–3.
   PubMedGoogle Scholar
• Gangadharan B, Bapat M, Rossa J, Antrobus R, Chittenden D, Kampa B, et al. (2012). Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study. PLoS One, 7, e39603.
   Google Scholar
• Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. (1998). Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med, 129, 36–8.
   PubMed Web of Science ®Google Scholar
• Gloria L, Serejo F, Cruz E, Freitas J, Costa A, Ramalho F, et al. (1998). Diphenylhydantoin-induced hepatitis: a case report. Hepatogastroenterology, 45, 411–4.
   PubMedGoogle Scholar
• Goldkind L, Laine L. (2006). A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf, 15, 213–20.
   PubMed Web of Science ®Google Scholar
• Goo YA, Cain K, Jarrett M, Smith L, Voss J, Tolentino E, et al. (2012). Urinary proteome analysis of irritable bowel syndrome (IBS) symptom subgroups. J Proteome Res, 11, 5650–62.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Drinkard CR, Shatin D. (2003). Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol, 98, 175–9.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. (2001). Liver enzyme monitoring in patients treated with troglitazone. JAMA, 286, 831–3.
   PubMed Web of Science ®Google Scholar
• Grieco A, Miele L, Giorgi A, Civello IM, Gasbarrini G. (2002). Acute cholestatic hepatitis associated with celecoxib. Ann Pharmacother, 36, 1887–9.
   PubMed Web of Science ®Google Scholar
• Gupta NK, Lewis JH. (2008). Review article: The use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther, 28, 1021–41.
   PubMed Web of Science ®Google Scholar
• Gyamfi MA, Damjanov I, French S, Wan YJ. (2008a). The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury. Biochem Pharmacol, 75, 981–95.
   PubMed Web of Science ®Google Scholar
• Gyamfi MA, He L, French SW, Damjanov I, Wan YJ. (2008b). Hepatocyte retinoid X receptor alpha-dependent regulation of lipid homeostasis and inflammatory cytokine expression contributes to alcohol-induced liver injury. J Pharmacol Exp Ther, 324, 443–53.
   PubMed Web of Science ®Google Scholar
• Habior A, Walewska-Zielecka B, Butruk E. (1994). Hepatocellular-cholestatic liver injury due to amoxycillin-clavulanic acid combination. Clin Investig, 72, 616–8.
   PubMedGoogle Scholar
• Hackstein H, Mohl W, Puschel W, Stallmach A, Zeitz M. (1998). Diclofenac-associated acute cholestatis hepatitis. Z Gastroenterol, 36, 385–9.
   PubMedGoogle Scholar
• Hadzic N, Portmann B, Davies ET, Mowat AP, Mieli-Vergani G. (1990). Acute liver failure induced by carbamazepine. Arch Dis Child, 65, 315–7.
   PubMed Web of Science ®Google Scholar
• Hammel P, Larrey D, Bernuau J, Kalafat M, Freneaux E, Babany G, et al. (1990). Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer's disease. J Clin Gastroenterol, 12, 329–31.
   PubMed Web of Science ®Google Scholar
• Handa S, Maruyama N, Ishigami A. (2009). Over-expression of Senescence Marker Protein-30 decreases reactive oxygen species in human hepatic carcinoma Hep G2 cells. Biol Pharm Bull, 32, 1645–8.
   PubMed Web of Science ®Google Scholar
• Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ. (2010). Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos, 38, 2293–301.
   PubMed Web of Science ®Google Scholar
• Hartland SN, Murphy F, Aucott RL, Abergel A, Zhou X, Waung J, et al. (2009). Active matrix metalloproteinase-2 promotes apoptosis of hepatic stellate cells via the cleavage of cellular N-cadherin. Liver Int, 29, 966–78.
   PubMed Web of Science ®Google Scholar
• Hassall E, Israel DM, Gunasekaran T, Steward D. (1990). Halothane hepatitis in children. J Pediatr Gastroenterol Nutr, 11, 553–7.
   PubMedGoogle Scholar
• Hautekeete ML, Horsmans Y, Van Waeyenberge C, Demanet C, Henrion J, Verbist L, et al. (1999). HLA association of amoxicillin-clavulanate–induced hepatitis. Gastroenterology, 117, 1181–6.
   PubMed Web of Science ®Google Scholar
• Helfgott SM, Sandberg-Cook J, Zakim D, Nestler J. (1990). Diclofenac-associated hepatotoxicity. JAMA, 264, 2660–2.
   PubMed Web of Science ®Google Scholar
• Henney JE. (2000). Withdrawal of troglitazone and cisapride. JAMA, 283, 2228.
   PubMedGoogle Scholar
• Hinson JA, Roberts DW, James LP. (2010). Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol, 369–405.
   Google Scholar
• Hiyoshi M, Konishi H, Uemura H, Matsuzaki H, Tsukamoto H, Sugimoto R, et al. (2009). D-Dopachrome tautomerase is a candidate for key proteins to protect the rat liver damaged by carbon tetrachloride. Toxicology, 255, 6–14.
   PubMedGoogle Scholar
• Hopen G, Nesthus I, Laerum OD. (1981). Fatal carbamazepine-associated hepatitis. Report of two cases. Acta Med Scand, 210, 333–5.
   Google Scholar
• Hunter EB, Johnston PE, Tanner G, Pinson CW, Awad JA. (1999). Bromfenac (Duract)-associated hepatic failure requiring liver transplantation. Am J Gastroenterol, 94, 2299–301.
   PubMed Web of Science ®Google Scholar
• Husi H, Stephens N, Cronshaw A, Macdonald A, Gallagher I, Greig C, et al. (2011). Proteomic analysis of urinary upper gastrointestinal cancer markers. Proteomics Clin Appl, 5, 289–99.
   PubMedGoogle Scholar
• Ijaz K, Jereb JA, Lambert LA, Bower WA, Spradling PR, Mcelroy PD, et al. (2006). Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis, 42, 346–55.
   PubMedGoogle Scholar
• Ikegame S, Wakamatsu K, Fujita M, Nakanishi Y, Kajiki A. (2011). A case of isoniazid-induced liver injury diagnosed by use of the DLST, and successful reintroduction of isoniazid for pleural tuberculosis. J Infect Chemother, 17, 530–3.
   PubMedGoogle Scholar
• Ishida Y, Kondo T, Kimura A, Tsuneyama K, Takayasu T, Mukaida N. (2006). Opposite roles of neutrophils and macrophages in the pathogenesis of acetaminophen-induced acute liver injury. Eur J Immunol, 36, 1028–38.
   PubMed Web of Science ®Google Scholar
• Itoh K, Ishii T, Wakabayashi N, Yamamoto M. (1999). Regulatory mechanisms of cellular response to oxidative stress. Free Radic Res, 31, 319–24.
   PubMed Web of Science ®Google Scholar
• Iveson TJ, Ryley NG, Kelly PM, Trowell JM, Mcgee JO, Chapman RW. (1990). Diclofenac associated hepatitis. J Hepatol, 10, 85–9.
   PubMed Web of Science ®Google Scholar
• Jackson DH, Banks RE. (2010). Banking of clinical samples for proteomic biomarker studies: a consideration of logistical issues with a focus on pre-analytical variation. Proteomics Clin Appl, 4, 250–70.
   PubMed Web of Science ®Google Scholar
• Jacobs WH. (1976). Intrahepatic cholestasis following the use of Atromid-S. Am J Gastroenterol, 66, 69–71.
   PubMedGoogle Scholar
• Jaeschke H, Liu J. (2007). Neutrophil depletion protects against murine acetaminophen hepatotoxicity: another perspective. Hepatology, 45, 1588–9; author reply 1589.
   PubMed Web of Science ®Google Scholar
• Jaeschke H, Mcgill MR, Williams CD. (2013). Pathophysiological relevance of neutrophils in acetaminophen hepatotoxicity. Hepatology, 57, 419.
   PubMedGoogle Scholar
• Jaeschke H, Williams CD, Ramachandran A, Bajt ML. (2012). Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int, 32, 8–20.
   PubMed Web of Science ®Google Scholar
• Jain SK, Rohatgi A, Raman KK, Sharma VK. (1995). Study of serum prealbumin and serum alpha fetoprotein in cases of fulminant hepatic failure. J Assoc Physicians India, 43, 462–3.
   PubMedGoogle Scholar
• James LP, Gill P, Simpson P. (2013). Predicting risk in patients with acetaminophen overdose. Expert Rev Gastroenterol Hepatol, 7, 509–12.
   PubMed Web of Science ®Google Scholar
• Jayapalan JJ, Ng KL, Shuib AS, Razack AH, Hashim OH. (2013). Urine of patients with early prostate cancer contains lower levels of light chain fragments of inter-alpha-trypsin inhibitor and saposin B but increased expression of an inter-alpha-trypsin inhibitor heavy chain 4 fragment. Electrophoresis, 34, 1663–9.
   PubMed Web of Science ®Google Scholar
• Jayaraman A, Roberts KA, Yoon J, Yarmush DM, Duan X, Lee K, Yarmush ML. (2005). Identification of neutrophil gelatinase-associated lipocalin (NGAL) as a discriminatory marker of the hepatocyte-secreted protein response to IL-1beta: a proteomic analysis. Biotechnol Bioeng, 91, 502–15.
   PubMedGoogle Scholar
• Ju C. (2012a). Damage-associated molecular patterns: their impact on the liver and beyond during acetaminophen overdose. Hepatology, 56, 1599–601.
   PubMedGoogle Scholar
• Ju C, Reilly T. (2012b). Role of immune reactions in drug-induced liver injury (DILI). Drug Metab Rev, 44, 107–15.
   PubMed Web of Science ®Google Scholar
• Ju C, Reilly TP, Bourdi M, Radonovich MF, Brady JN, George JW, Pohl LR. (2002). Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice. Chem Res Toxicol, 15, 1504–13.
   PubMed Web of Science ®Google Scholar
• Kanel GC, Cassidy W, Shuster L, Reynolds TB. (1990). Cocaine-induced liver cell injury: comparison of morphological features in man and in experimental models. Hepatology, 11, 646–51.
   PubMed Web of Science ®Google Scholar
• Kaplowitz N. (2005). Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov, 4, 489–99.
   PubMed Web of Science ®Google Scholar
• Kassianides C, Nussenblatt R, Palestine AG, Mellow SD, Hoofnagle JH. (1990). Liver injury from cyclosporine A. Dig Dis Sci, 35, 693–7.
   PubMed Web of Science ®Google Scholar
• Kenna JG, Neuberger J, Mieli-Vergani G, Mowat AP, Williams R. (1987). Halothane hepatitis in children. Br Med J (Clin Res Ed), 294, 1209–11.
   PubMedGoogle Scholar
• Kentsis A. (2011). Challenges and opportunities for discovery of disease biomarkers using urine proteomics. Pediatr Int, 53, 1–6.
   PubMedGoogle Scholar
• Kim JS, Jang YR, Lee JW, Kim JY, Jung YK, Chung DH, et al. (2011). A case of amoxicillin-induced hepatocellular liver injury with bile-duct damage. Korean J Hepatol, 17, 229–32.
   Google Scholar
• Kim TH, Kim BH, Kim YW, Yang DM, Han YS, Dong SH, et al. (2003). Liver cirrhosis developed after ketoconazole-induced acute hepatic injury. J Gastroenterol Hepatol, 18, 1426–9.
   PubMedGoogle Scholar
• Kishida T, Onozato T, Kanazawa T, Tanaka S, Kuroda J. (2012). Increase in covalent binding of 5-hydroxydiclofenac to hepatic tissues in rats co-treated with lipopolysaccharide and diclofenac: involvement in the onset of diclofenac-induced idiosyncratic hepatotoxicity. J Toxicol Sci, 37, 1143–56.
   PubMedGoogle Scholar
• Kiso K, Ueno S, Fukuda M, Ichi I, Kobayashi K, Sakai T, et al. (2012). The role of Kupffer cells in carbon tetrachloride intoxication in mice. Biol Pharm Bull, 35, 980–3.
   PubMedGoogle Scholar
• Kistler AD, Serra AL, Siwy J, Poster D, Krauer F, Torres VE, et al. (2013). Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One, 8, e53016.
   PubMed Web of Science ®Google Scholar
• Kleiner DE. (2009). The pathology of drug-induced liver injury. Semin Liver Dis, 29, 364–72.
   PubMed Web of Science ®Google Scholar
• Klys M, Wozniak K, Rojek S, Rzepecka-Wozniak E, Kowalski P. (2008). Ethanol-related death of a child: an unusual case report. Forensic Sci Int, 179, e1–4.
   PubMedGoogle Scholar
• Knight TE, Shikuma CY, Knight J. (1991). Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. J Am Acad Dermatol, 25, 398–400.
   PubMedGoogle Scholar
• Kock K, Ferslew BC, Netterberg I, Yang K, Urban TJ, Swaan PW, et al. (2014). Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos, 42, 665–74.
   PubMed Web of Science ®Google Scholar
• Koniaris LG, Seibel JA, Geschwind JF, Sitzmann JV. (2003). Can ethanol therapies injure the bile ducts? Hepatogastroenterology, 50, 69–72.
   PubMedGoogle Scholar
• Lai MW, Klein-Schwartz W, Rodgers GC, Abrams JY, Haber DA, Bronstein AC, Wruk KM. (2006). 2005 Annual Report of the American Association of Poison Control Centers’ national poisoning and exposure database. Clin Toxicol (Phila), 44, 803–932.
   PubMed Web of Science ®Google Scholar
• Langman G, Hall PM, Todd G. (2001). Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol, 16, 1395–401.
   PubMed Web of Science ®Google Scholar
• Larrey D, Vial T, Micaleff A, Babany G, Morichau-Beauchant M, Michel H, Benhamou JP. (1992). Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut, 33, 368–71.
   PubMed Web of Science ®Google Scholar
• Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. (2005). Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology, 42, 1364–72.
   PubMed Web of Science ®Google Scholar
• Laskin DL, Gardner CR, Price VF, Jollow DJ. (1995). Modulation of macrophage functioning abrogates the acute hepatotoxicity of acetaminophen. Hepatology, 21, 1045–50.
   PubMed Web of Science ®Google Scholar
• Laurent S, Rahier J, Geubel AP, Lerut J, Horsmans Y. (2000). Subfulminant hepatitis requiring liver transplantation following ibuprofen overdose. Liver, 20, 93–4.
   PubMedGoogle Scholar
• Lee AM, Mennone JZ, Jones RC, Paul WS. (2002). Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis, 6, 995–1000.
   PubMed Web of Science ®Google Scholar
• Lee CH, Wang JD, Chen PC. (2010). Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol Drug Saf, 19, 708–14.
   PubMed Web of Science ®Google Scholar
• Lee GH, Bhandary B, Lee EM, Park JK, Jeong KS, Kim IK, et al. (2011a). The roles of ER stress and P450 2E1 in CCl(4)-induced steatosis. Int J Biochem Cell Biol, 43, 1469–82.
   PubMedGoogle Scholar
• Lee SM, Park JS, Norwitz ER, Kim SM, Kim BJ, Park CW, et al. (2011b). Characterization of discriminatory urinary proteomic biomarkers for severe preeclampsia using SELDI-TOF mass spectrometry. J Perinat Med, 39, 391–6.
   PubMed Web of Science ®Google Scholar
• Levander HG. (1980). Granulomatous hepatitis in a patient receiving carbamazepine. Acta Med Scand, 208, 333–5.
   PubMed Web of Science ®Google Scholar
• Li H, Heller DS, Leevy CB, Zierer KG, Klein KM. (2000). Troglitazone-induced fulminant hepatitis: report of a case with autopsy findings. J Diabetes Complications, 14, 175–7.
   PubMed Web of Science ®Google Scholar
• Li LM, Chen L, Deng GH, Tan WT, Dan YJ, Wang RQ, Chen WS. (2012). SLCO1B1 *15 haplotype is associated with rifampin-induced liver injury. Mol Med Rep, 6, 75–82.
   PubMed Web of Science ®Google Scholar
• Lieber CS. (1990). Mechanism of ethanol induced hepatic injury. Pharmacol Ther, 46, 1–41.
   PubMed Web of Science ®Google Scholar
• Lindgren A, Olsson R. (1993). Liver damage from low-dose oral contraceptives. J Intern Med, 234, 287–92.
   PubMed Web of Science ®Google Scholar
• Lings S. (1988). Halothane related liver affection in an anaesthetist. Br J Ind Med, 45, 716–7.
   PubMedGoogle Scholar
• Liu ZX, Han D, Gunawan B, Kaplowitz N. (2006). Neutrophil depletion protects against murine acetaminophen hepatotoxicity. Hepatology, 43, 1220–30.
   PubMed Web of Science ®Google Scholar
• Luzzati R, Giacomazzi D, Franchi F, Barcobello M, Vento S. (2007). Life-threatening, multiple hypersensitivity reactions induced by rifampicin in one patient with pulmonary tuberculosis. South Med J, 100, 854–6.
   PubMedGoogle Scholar
• Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, et al. (1998). Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med, 128, 176–85.
   PubMedGoogle Scholar
• Manyike PT, Kharasch ED, Kalhorn TF, Slattery JT. (2000). Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ther, 67, 275–82.
   PubMed Web of Science ®Google Scholar
• Marques PE, Amaral SS, Menezes GB. (2013). Reply: To PMID 22532075. Hepatology, 57, 420–1.
   PubMedGoogle Scholar
• Marques PE, Amaral SS, Pires DA, Nogueira LL, Soriani FM, Lima BH, et al. (2012). Chemokines and mitochondrial products activate neutrophils to amplify organ injury during mouse acute liver failure. Hepatology, 56, 1971–82.
   PubMed Web of Science ®Google Scholar
• Martin JL, Dubbink DA, Plevak DJ, Peronne A, Taswell HF, Hay EJ, et al. (1992). Halothane hepatitis 28 years after primary exposure. Anesth Analg, 74, 605–8.
   PubMed Web of Science ®Google Scholar
• McGill MR, Lebofsky M, Norris HR, Slawson MH, Bajt ML, Xie Y, et al. (2013). Plasma and liver acetaminophen-protein adduct levels in mice after acetaminophen treatment: dose-response, mechanisms, and clinical implications. Toxicol Appl Pharmacol, 269, 240–9.
   PubMed Web of Science ®Google Scholar
• McGill MR, Sharpe MR, Williams CD, Taha M, Curry SC, Jaeschke H. (2012). The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J Clin Invest, 122, 1574–83.
   PubMed Web of Science ®Google Scholar
• Meadows M. (2001). Serious liver injury. Leading reason for drug removals, restrictions. FDA Consum, 35, 8–9.
   Google Scholar
• Migneco G, Mascarella A, La Ferla A, Attianese R. (1986). Clofibrate hepatitis. A case report. Minerva Med, 77, 799–800.
   PubMedGoogle Scholar
• Millard PS, Wilcosky TC, Reade-Christopher SJ, Weber DJ. (1996). Isoniazid-related fatal hepatitis. West J Med, 164, 486–91.
   PubMedGoogle Scholar
• Miller M, Walsh S, Atirh A, Huang JT, Ferguson MA, Dillon JF. (2014). The serum proteome of non-alcoholic fatty liver disease – a multimodal approach to discovery of biomarkers of non-alcoholic steatohepatitis. J Gastroenterol Hepatol doi:10.1111/jgh.12614
   PubMedGoogle Scholar
• Miller TJ, Knapton A, Adeyemo O, Noory L, Weaver J, Hanig JP. (2008). Cytochrome c: a non-invasive biomarker of drug-induced liver injury. J Appl Toxicol, 28, 815–28.
   PubMed Web of Science ®Google Scholar
• Mischak H, Kolch W, Aivaliotis M, Bouyssie D, Court M, Dihazi H, et al. (2010). Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl, 4, 464–78.
   PubMed Web of Science ®Google Scholar
• Mitchell MC, Boitnott JK, Arregui A, Maddrey WC. (1981). Granulomatous hepatitis associated with carbamazepine therapy. Am J Med, 71, 733–5.
   PubMed Web of Science ®Google Scholar
• Mockli G, Crowley M, Stern R, Warnock ML. (1989). Massive hepatic necrosis in a child after administration of phenobarbital. Am J Gastroenterol, 84, 820–2.
   PubMedGoogle Scholar
• Moore RA, Greenberg E, Tangen L. (1995). Cyclosporine-induced worsening of hepatic dysfunction in a patient with Crohn's disease and enterocutaneous fistula. South Med J, 88, 843–4.
   PubMedGoogle Scholar
• Moses PL, Schroeder B, Alkhatib O, Ferrentino N, Suppan T, Lidofsky SD. (1999). Severe hepatotoxicity associated with bromfenac sodium. Am J Gastroenterol, 94, 1393–6.
   PubMed Web of Science ®Google Scholar
• Mullick FG, Ishak KG. (1980). Hepatic injury associated with diphenylhydantoin therapy. A clinicopathologic study of 20 cases. Am J Clin Pathol, 74, 442–52.
   PubMed Web of Science ®Google Scholar
• Munro HM, Snider SJ, Magee JC. (1998). Halothane-associated hepatitis in a 6-year-old boy: evidence for native liver regeneration following failed treatment with auxiliary liver transplantation. Anesthesiology, 89, 524–7.
   PubMedGoogle Scholar
• Nachimuthu S, Volfinzon L, Gopal L. (2001). Acute hepatocellular and cholestatic injury in a patient taking celecoxib. Postgrad Med J, 77, 548–50.
   PubMed Web of Science ®Google Scholar
• Nagaoka MR, Kouyoumdjian M, Borges DR. (2003). Hepatic clearance of tissue-type plasminogen activator and plasma kallikrein in experimental liver fibrosis. Liver Int, 23, 476–83.
   PubMedGoogle Scholar
• Naisbitt DJ, Sanderson LS, Meng X, Stachulski AV, Clarke SE, Park BK. (2007). Investigation of the immunogenicity of diclofenac and diclofenac metabolites. Toxicol Lett, 168, 45–50.
   PubMed Web of Science ®Google Scholar
• Nathani MG, Mutchnick MG, Tynes DJ, Ehrinpreis MN. (1998). An unusual case of amoxicillin/clavulanic acid-related hepatotoxicity. Am J Gastroenterol, 93, 1363–5.
   PubMed Web of Science ®Google Scholar
• Nathwani RA, Pais S, Reynolds TB, Kaplowitz N. (2005). Serum alanine aminotransferase in skeletal muscle diseases. Hepatology, 41, 380–2.
   PubMed Web of Science ®Google Scholar
• Navarro-Munoz M, Ibernon M, Bonet J, Perez V, Pastor MC, Bayes B, et al. (2012). Uromodulin and alpha(1)-antitrypsin urinary peptide analysis to differentiate glomerular kidney diseases. Kidney Blood Press Res, 35, 314–25.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Yang CS, Pickett CB. (2004). The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med, 37, 433–41.
   PubMed Web of Science ®Google Scholar
• Nightingale SL. (1998). From the Food and Drug Administration. JAMA, 279, 9.
   PubMedGoogle Scholar
• Nomura F, Tomonaga T, Sogawa K, Ohashi T, Nezu M, Sunaga M, et al. (2004). Identification of novel and downregulated biomarkers for alcoholism by surface enhanced laser desorption/ionization-mass spectrometry. Proteomics, 4, 1187–94.
   PubMedGoogle Scholar
• O'Beirne JP, Cairns SR. (2001). Drug Points: Cholestatic hepatitis in association with celecoxib. BMJ, 323, 23.
   PubMed Web of Science ®Google Scholar
• Osman KA, Osman MM, Ahmed MH. (2007). Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going? Expert Opin Drug Saf, 6, 1–4.
   PubMed Web of Science ®Google Scholar
• Otedo AE. (2004). Halothane induced hepatitis: case report. East Afr Med J, 81, 538–9.
   PubMedGoogle Scholar
• Ouellette GS, Slitzky BE, Gates JA, Lagarde S, West AB. (1991). Reversible hepatitis associated with diclofenac. J Clin Gastroenterol, 13, 205–10.
   PubMedGoogle Scholar
• Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. (2008). The current state of serum biomarkers of hepatotoxicity. Toxicology, 245, 194–205.
   PubMed Web of Science ®Google Scholar
• Ozgur O, Hacihasanoglu A, Karti SS, Ovali E. (2003). Nimesulide-induced fulminant hepatitis. Turk J Gastroenterol, 14, 208–10.
   PubMedGoogle Scholar
• Papale M, Pedicillo MC, Thatcher BJ, Di Paolo S., Lo Muzio L., Bufo, P., et al. (2007). Urine profiling by SELDI-TOF/MS: monitoring of the critical steps in sample collection, handling and analysis. J Chromatogr B Analyt Technol Biomed Life Sci, 856, 205–13.
   PubMedGoogle Scholar
• Parker WA, Shearer CA. (1979). Phenytoin hepatotoxicity: a case report and review. Neurology, 29, 175–8.
   PubMed Web of Science ®Google Scholar
• Pelsers MM, Morovat A, Alexander GJ, Hermens WT, Trull AK, Glatz JF. (2002). Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. Clin Chem, 48, 2055–7.
   PubMed Web of Science ®Google Scholar
• Perino LE, Warren GH, Levine JS. (1987). Cocaine-induced hepatotoxicity in humans. Gastroenterology, 93, 176–80.
   PubMed Web of Science ®Google Scholar
• Persson M, Loye AF, Mow T, Hornberg JJ. (2013). A high content screening assay to predict human drug-induced liver injury during drug discovery. J Pharmacol Toxicol Methods, 68, 302–13.
   PubMed Web of Science ®Google Scholar
• Phillips CA, Cera PJ, Mangan TF, Newman ED. (1992). Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol, 19, 229–33.
   PubMedGoogle Scholar
• Pinto HC, Baptista A, Camilo ME, De Costa EB, Valente A, De Moura MC. (1995). Tamoxifen-associated steatohepatitis–report of three cases. J Hepatol, 23, 95–7.
   PubMed Web of Science ®Google Scholar
• Pisitkun T, Johnstone R, Knepper MA. (2006). Discovery of urinary biomarkers. Mol Cell Proteomics, 5, 1760–71.
   PubMed Web of Science ®Google Scholar
• Poon GK, Chen Q, Teffera Y, Ngui JS, Griffin PR, Braun MP, et al. (2001). Bioactivation of diclofenac via benzoquinone imine intermediates-identification of urinary mercapturic acid derivatives in rats and humans. Drug Metab Dispos, 29, 1608–13.
   PubMed Web of Science ®Google Scholar
• Porceddu M, Buron N, Roussel C, Labbe G, Fromenty B, Borgne-Sanchez A. (2012). Prediction of Liver Injury Induced by Chemicals in Human with a Multiparametric Assay on Isolated Mouse Liver Mitochondria. Toxicol Sci, 129, 332–45.
   PubMed Web of Science ®Google Scholar
• Poynard T, De Ledinghen V., Zarski JP, Stanciu C, Munteanu M, Vergniol J, et al. (2012). Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. J Hepatol, 56, 541–8.
   PubMedGoogle Scholar
• Pratt DS, Knox TA, Erban J. (1995). Tamoxifen-induced steatohepatitis. Ann Intern Med, 123, 236.
   PubMed Web of Science ®Google Scholar
• Prince MI, Burt AD, Jones DE. (2002). Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut, 50, 436–9.
   PubMed Web of Science ®Google Scholar
• Proctor WR, Chakraborty M, Chea LS, Morrison JC, Berkson JD, Semple K, et al. (2013). Eosinophils mediate the pathogenesis of halothane-induced liver injury in mice. Hepatology, 57, 2026–36.
   PubMed Web of Science ®Google Scholar
• Prot JM, Briffaut AS, Letourneur F, Chafey P, Merlier F, Grandvalet Y, et al. (2011). Integrated proteomic and transcriptomic investigation of the acetaminophen toxicity in liver microfluidic biochip. PLoS One, 6, e21268.
   Google Scholar
• Qureshi MA, Saeed F, Hussain T. (2007). Halothane induced fulminant hepatic failure. J Coll Physicians Surg Pak, 17, 103–4.
   PubMedGoogle Scholar
• Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL. (2011). Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf, 20, 772–7.
   PubMed Web of Science ®Google Scholar
• Ramachandran R, Kakar S. (2009). Histological patterns in drug-induced liver disease. J Clin Pathol, 62, 481–92.
   PubMed Web of Science ®Google Scholar
• Ramm S, Mally A. (2013). Role of drug-independent stress factors in liver injury associated with diclofenac intake. Toxicology, 312, 83–96.
   PubMed Web of Science ®Google Scholar
• Ray SD, Kamendulis LM, Gurule MW, Yorkin RD, Corcoran GB. (1993). Ca2 + antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. FASEB J, 7, 453–63.
   PubMed Web of Science ®Google Scholar
• Reddy KR, Brillant P, Schiff ER. (1989). Amoxicillin-clavulanate potassium-associated cholestasis. Gastroenterology, 96, 1135–41.
   PubMed Web of Science ®Google Scholar
• Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Caliz I, Gonzalez-Jimenez A, et al. (2014). Use of Hy s Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients with Drug-induced Liver Injury. Gastroenterology, doi:10.1053/j.gastro.2014.03.050.
   Google Scholar
• Rodriguez Gonzalez F, Jimenez Romero C, Rodriguez Romano D, Loinaz Segurola C, Marques Medina E, Perez Saborido B, et al. (2002). Orthotopic liver transplantation with 100 hepatic allografts from donors over 60 years old. Transplant Proc, 34, 233–4.
   PubMedGoogle Scholar
• Roth RA, Ganey PE. (2010). Intrinsic versus idiosyncratic drug-induced hepatotoxicity–two villains or one? J Pharmacol Exp Ther, 332, 692–7.
   PubMed Web of Science ®Google Scholar
• Roy AK, Mahoney HC, Levine RA. (1993). Phenytoin-induced chronic hepatitis. Dig Dis Sci, 38, 740–3.
   PubMedGoogle Scholar
• Saberi B, Ybanez MD, Johnson HS, Gaarde WA, Han D, Kaplowitz N. (2013). Protein kinase C (PKC) participates in acetaminophen hepatotoxicity through c-jun-N-terminal kinase (JNK)-dependent and -independent signaling pathways. Hepatology, 59, 1543–54.
   Google Scholar
• Salamone F, Galvano F, Cappello F, Mangiameli A, Barbagallo I, Li Volti G. (2012). Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl Res, 159, 477–86.
   PubMed Web of Science ®Google Scholar
• Sallie RW, Mckenzie T, Reed WD, Quinlan MF, Shilkin KB. (1991). Diclofenac hepatitis. Aust N Z J Med, 21, 251–5.
   PubMedGoogle Scholar
• Sasaki E, Matsuo K, Iida A, Tsuneyama K, Fukami T, Nakajima M, Yokoi T. (2013). A novel mouse model for phenytoin-induced liver injury: involvement of immune-related factors and P450-mediated metabolism. Toxicol Sci, 136, 250–63.
   PubMed Web of Science ®Google Scholar
• Sato K, Ueda Y, Ueno K, Okamoto K, Iizuka H, Katsuda S. (2005). Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. Virchows Arch, 447, 996–9.
   PubMedGoogle Scholar
• Savino R, Paduano S, Preiano M, Terracciano R. (2012). The proteomics big challenge for biomarkers and new drug-targets discovery. Int J Mol Sci, 13, 13926–48.
   PubMed Web of Science ®Google Scholar
• Sawaishi Y, Komatsu K, Takeda O, Tazawa Y, Takahashi I, Hayasaka K, Takada G. (1992). A case of tubulo-interstitial nephritis with exfoliative dermatitis and hepatitis due to phenobarbital hypersensitivity. Eur J Pediatr, 151, 69–72.
   PubMedGoogle Scholar
• Sbeit W, Krivoy N, Shiller M, Farah R, Cohen HI, Struminger L, Reshef R. (2001). Nimesulide-induced acute hepatitis. Ann Pharmacother, 35, 1049–52.
   PubMedGoogle Scholar
• Schattner A, Sokolovskaya N, Cohen J. (2000). Fatal hepatitis and renal failure during treatment with nimesulide. J Intern Med, 247, 153–5.
   PubMed Web of Science ®Google Scholar
• Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P. (2004). Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int, 65, 323–32.
   PubMed Web of Science ®Google Scholar
• Scheuer PJ, Summerfield JA, Lal S, Sherlock S. (1974). Rifampicin hepatitis. A clinical and histological study. Lancet, 1, 421–5.
   PubMed Web of Science ®Google Scholar
• Schiano T, Dolehide K, Hart J, Baker AL. (2000). Severe but reversible hepatitis induced by troglitazone. Dig Dis Sci, 45, 1039–42.
   PubMed Web of Science ®Google Scholar
• Scully LJ, Clarke D, Barr RJ. (1993). Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci, 38, 744–51.
   PubMed Web of Science ®Google Scholar
• Seki E, Brenner DA, Karin M. (2012). A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology, 143, 307–20.
   PubMed Web of Science ®Google Scholar
• Semfke A, Wackernagel C, Vier H, Schutz A, Wiechmann V, Gillissen A. (2009). Histologically proven isoniazid hepatoxicity in complicated tuberculous salpingitis. Ther Adv Respir Dis, 3, 159–62.
   PubMedGoogle Scholar
• Senior JR. (2010). Unintended hepatic adverse events associated with cancer chemotherapy. Toxicol Pathol, 38, 142–7.
   PubMed Web of Science ®Google Scholar
• Shapiro PA, Antonioli DA, Peppercorn MA. (1980). Barbiturate-induced submassive hepatic necrosis. Report of a case and review of the literature. Am J Gastroenterol, 74, 270–3.
   PubMedGoogle Scholar
• Silvain C, Fort E, Levillain P, Labat-Labourdette J, Beauchant M. (1992). Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid. Dig Dis Sci, 37, 150–2.
   PubMedGoogle Scholar
• Smilkstein MJ, Bronstein AC, Linden C, Augenstein WL, Kulig KW, Rumack BH. (1991). Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med, 20, 1058–63.
   PubMed Web of Science ®Google Scholar
• Smyth R, Munday MR, York MJ, Clarke CJ, Dare T, Turton JA. (2009). Dose response and time course studies on superoxide dismutase as a urinary biomarker of carbon tetrachloride-induced hepatic injury in the Hanover Wistar rat. Int J Exp Pathol, 90, 500–11.
   PubMedGoogle Scholar
• Smyth R, Turton JA, Clarke CJ, York MJ, Dare TO, Lane CS, Munday MR. (2008). Identification of superoxide dismutase as a potential urinary marker of carbon tetrachloride-induced hepatic toxicity. Food Chem Toxicol, 46, 2972–83.
   PubMedGoogle Scholar
• Soffer EE, Taylor RJ, Bertram PD, Haggitt RC, Levinson MJ. (1983). Carbamazepine-induced liver injury. South Med J, 76, 681–3.
   PubMedGoogle Scholar
• Soga T, Sugimoto M, Honma M, Mori M, Igarashi K, Kashikura K, et al. (2011). Serum metabolomics reveals gamma-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. J Hepatol, 55, 896–905.
   PubMed Web of Science ®Google Scholar
• Somparn P, Hirankarn N, Leelahavanichkul A, Khovidhunkit W, Thongboonkerd V, Avihingsanon Y. (2012). Urinary proteomics revealed prostaglandin H(2)D-isomerase, not Zn-alpha2-glycoprotein, as a biomarker for active lupus nephritis. J Proteomics, 75, 3240–7.
   PubMed Web of Science ®Google Scholar
• Sternlieb P, Robinson RM. (1978). Stevens-Johnson syndrome plus toxic hepatitis due to ibuprofen. N Y State J Med, 78, 1239–43.
   PubMedGoogle Scholar
• Stirnimann G, Kessebohm K, Lauterburg B. (2010). Liver injury caused by drugs: an update. Swiss Med Wkly, 140, w13080.
   PubMed Web of Science ®Google Scholar
• Stricker BH, Van Den Broek JW, Keuning J, Eberhardt W, Houben HG, Johnson M, Blok AP. (1989). Cholestatic hepatitis due to antibacterial combination of amoxicillin and clavulanic acid (augmentin). Dig Dis Sci, 34, 1576–80.
   PubMed Web of Science ®Google Scholar
• Su L, Cao L, Zhou R, Jiang Z, Xiao K, Kong W, et al. (2013). Identification of novel biomarkers for sepsis prognosis via urinary proteomic analysis using iTRAQ labeling and 2D-LC-MS/MS. PLoS One, 8, e54237.
   PubMed Web of Science ®Google Scholar
• Sutherland DE, Smith WA. (1992). Chemical hepatitis associated with occupational exposure to halothane in a research laboratory. Vet Hum Toxicol, 34, 423–4.
   PubMedGoogle Scholar
• Tack CJ, Smits P, Demacker PN, Stalenhoef AF. (1998). Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care, 21, 796–9.
   PubMed Web of Science ®Google Scholar
• Tan XF, Chen F, Wu SS, Shi Y, Liu DC, Chen Z. (2010). Science letters: Proteomic analysis of differentially expressed proteins in mice with concanavalin A-induced hepatitis. J Zhejiang Univ Sci B, 11, 221–6.
   PubMedGoogle Scholar
• Taneja S, Sen S, Gupta VK, Aggarwal R, Jameel S. (2009). Plasma and urine biomarkers in acute viral hepatitis E. Proteome Sci, 7, 39.
   PubMed Web of Science ®Google Scholar
• Taylor JW, Stein MN, Murphy MJ, Mitros FA. (1984). Cholestatic liver dysfunction after long-term phenytoin therapy. Arch Neurol, 41, 500–1.
   PubMedGoogle Scholar
• Theodorescu D, Fliser D, Wittke S, Mischak H, Krebs R, Walden, M., et al. (2005). Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis, 26, 2797–808.
   PubMed Web of Science ®Google Scholar
• Thongboonkerd V. (2008). Urinary proteomics: towards biomarker discovery, diagnostics and prognostics. Mol Biosyst, 4, 810–5.
   PubMedGoogle Scholar
• Toghill PJ, Williams R, Stephens JD, Carroll JD. (1969). Acute hepatic necrosis following an overdose of paracetamol. Gastroenterology, 56, 773–6.
   PubMedGoogle Scholar
• Toledo CF, Kouyoumdjian M, Lanzoni VP, Borges DR. (1995). Plasma kallikrein clearance by the liver of chronic carbon tetrachloride-treated rats. J Gastroenterol Hepatol, 10, 165–8.
   PubMedGoogle Scholar
• Tran T, Lee WM. (2013). DILI: New Insights into Diagnosis and Management. Curr Hepat Rep, 12, 53–58.
   PubMedGoogle Scholar
• Tugnet N, Cooper SC, Douglas KM. (2012). Methotrexate therapy, rheumatoid arthritis, and life-threatening liver complications: should we be monitoring more closely? Scand J Rheumatol, 41, 163–4.
   PubMed Web of Science ®Google Scholar
• Tujios S, Fontana RJ. (2011). Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol, 8, 202–11.
   PubMed Web of Science ®Google Scholar
• van Erpecum KJ, Janssens AR, Kreuning J, Ruiter DJ, Kroon HM, Grond AJ. (1988). Generalized peliosis hepatis and cirrhosis after long-term use of oral contraceptives. Am J Gastroenterol, 83, 572–5.
   PubMedGoogle Scholar
• van Hoof M, Rahier J, Horsmans Y. (1996). Tamoxifen-induced steatohepatitis. Ann Intern Med, 124, 855–6.
   PubMedGoogle Scholar
• van Outryve S, Schrijvers D, Van Den Brande J, Wilmes P, Bogers J, Van Marck E, Vermorken JB. (2002). Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review. Neth J Med, 60, 216–22.
   PubMedGoogle Scholar
• van Steenbergen W, Peeters P, De Bondt J, Staessen D, Buscher H, Laporta T, et al. (1998). Nimesulide-induced acute hepatitis: evidence from six cases. J Hepatol, 29, 135–41.
   PubMed Web of Science ®Google Scholar
• van Swelm R., Laarakkers C, Blous L, Peters J, Blaney Davidson E, Van Der Kraan P, et al. (2012a). Acute acetaminophen intoxication leads to hepatic iron loading by decreased hepcidin synthesis. Toxicol Sci, 129, 225–33.
   PubMedGoogle Scholar
• van Swelm RP, Hadi M, Laarakkers CM, Masereeuw R, Groothuis GM, Russel FG. (2013a). Proteomic profiling in incubation medium of mouse, rat and human precision-cut liver slices for biomarker detection regarding acute drug-induced liver injury. J Appl Toxicol, doi:10.1002/jat.2917.
   PubMedGoogle Scholar
• van Swelm RP, Laarakkers CM, Kooijmans-Otero M, De Jong EM, Masereeuw R, Russel FG. (2013b). Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients. Toxicol Lett, 221, 219–24.
   PubMed Web of Science ®Google Scholar
• van Swelm RP, Laarakkers CM, Pertijs JC, Verweij V, Masereeuw R, Russel FG. (2013c). Urinary proteomic profiling reveals diclofenac-induced renal injury and hepatic regeneration in mice. Toxicol Appl Pharmacol, 269, 141–9.
   PubMedGoogle Scholar
• van Swelm RP, Laarakkers CM, van der Kuur EC, Morava-Kozicz E, Wevers RA, Augustijn KD, et al. (2012b). Identification of novel translational urinary biomarkers for acetaminophen-induced acute liver injury using proteomic profiling in mice. PLoS One, 7, e49524.
   Google Scholar
• Vanhoutte KJ, Laarakkers C, Marchiori E, Pickkers P, Wetzels JF, Willems JL, et al. (2007). Biomarker discovery with SELDI-TOF MS in human urine associated with early renal injury: evaluation with computational analytical tools. Nephrol Dial Transplant, 22, 2932–43.
   PubMed Web of Science ®Google Scholar
• Vaught J, Lockhart NC. (2012). The evolution of biobanking best practices. Clin Chim Acta, 413, 1569–75.
   PubMed Web of Science ®Google Scholar
• Verhamme M, Ramboer C, Van De Bruaene P, Inderadjaja N. (1989). Cholestatic hepatitis due to an amoxycillin/clavulanic acid preparation. J Hepatol, 9, 260–4.
   PubMedGoogle Scholar
• Verrotti A, Di Marco G, La Torre R, Pelliccia P, Chiarelli F. (2009). Nonalcoholic fatty liver disease during valproate therapy. Eur J Pediatr, 168, 1391–4.
   PubMed Web of Science ®Google Scholar
• Visser K, van der Heijde DM. (2009). Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol, 27, 1017–25.
   PubMed Web of Science ®Google Scholar
• Voigt MD, Workman B, Lombard C, Kirsch RE. (1997). Halothane hepatitis in a South African population–frequency and the influence of gender and ethnicity. S Afr Med J, 87, 882–5.
   PubMedGoogle Scholar
• Wagenaar LJ, Kuck EM, Hoekstra JB. (1999). Troglitazone. Is it all over? Neth J Med, 55, 4–12.
   PubMedGoogle Scholar
• Walsh K, Alexander G. (2000). Alcoholic liver disease. Postgrad Med J, 76, 280–6.
   PubMed Web of Science ®Google Scholar
• Wanless IR, Dore S, Gopinath N, Tan J, Cameron R, Heathcote EJ, et al. (1990). Histopathology of cocaine hepatotoxicity. Report of four patients. Gastroenterology, 98, 497–501.
   PubMed Web of Science ®Google Scholar
• Watkins PB. (2009). Biomarkers for the diagnosis and management of drug-induced liver injury. Semin Liver Dis, 29, 393–9.
   PubMed Web of Science ®Google Scholar
• Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR. (2008). Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology, 48, 1680–9.
   PubMed Web of Science ®Google Scholar
• Watkins PB, Whitcomb RW. (1998). Hepatic dysfunction associated with troglitazone. N Engl J Med, 338, 916–7.
   PubMed Web of Science ®Google Scholar
• Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. (1994). Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA, 271, 992–8.
   PubMed Web of Science ®Google Scholar
• Weden M, Glaumann H, Einarsson K. (1992). Protracted cholestasis probably induced by oral contraceptive. J Intern Med, 231, 561–5.
   PubMed Web of Science ®Google Scholar
• Weinstein A, Marlowe S, Korn J, Farouhar F. (1985). Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations. Am J Med, 79, 331–7.
   Google Scholar
• Weiss P, Mouallem M, Bruck R, Hassin D, Tanay A, Brickman CM, Farfel Z, Bar-Meir S. (1999). Nimesulide-induced hepatitis and acute liver failure. Isr Med Assoc J, 1, 89–91.
   PubMed Web of Science ®Google Scholar
• Welton DG. (1950). Exfoliative dermatitis and hepatitis due to phenobarbital. J Am Med Assoc, 143, 232–4.
   PubMed Web of Science ®Google Scholar
• Williams CD, Bajt ML, Sharpe MR, Mcgill MR, Farhood A, Jaeschke H. (2014). Neutrophil activation during acetaminophen hepatotoxicity and repair in mice and humans. Toxicol Appl Pharmacol, 275, 122–33.
   PubMed Web of Science ®Google Scholar
• Wong LL, Fan ST, Man K, Sit WH, Jiang PP, Jor IW, et al. (2011). Identification of liver proteins and their roles associated with carbon tetrachloride-induced hepatotoxicity. Hum Exp Toxicol, 30, 1369–81.
   PubMed Web of Science ®Google Scholar
• Xiao D, Meng FL, He LH, Gu YX, Zhang JZ. (2011). Analysis of the urinary peptidome associated with Helicobacter pylori infection. World J Gastroenterol, 17, 618–24.
   Google Scholar
• Yamaguchi M. (2011). Regucalcin and cell regulation: role as a suppressor protein in signal transduction. Mol Cell Biochem, 353, 101–37.
   PubMedGoogle Scholar
• Yamaguchi M, Isogai M, Shimada N. (1997). Potential sensitivity of hepatic specific protein regucalcin as a marker of chronic liver injury. Mol Cell Biochem, 167, 187–90.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Kikkawa R, Yamada H, Horii I. (2006). Investigation of proteomic biomarkers in in vivo hepatotoxicity study of rat liver: toxicity differentiation in hepatotoxicants. J Toxicol Sci, 31, 49–60.
   PubMedGoogle Scholar
• Yamamoto T, Langham RG, Ronco P, Knepper MA, Thongboonkerd V. (2008). Towards standard protocols and guidelines for urine proteomics: a report on the Human Kidney and Urine Proteome Project (HKUPP) symposium and workshop, 6 October 2007, Seoul, Korea and 1 November 2007, San Francisco, CA, USA. Proteomics, 8, 2156–9.
   PubMed Web of Science ®Google Scholar
• Yang N, Feng S, Shedden K, Xie X, Liu Y, Rosser CJ, et al. (2011). Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res, 17, 3349–59.
   PubMed Web of Science ®Google Scholar
• You Q, Cheng L, Reilly TP, Wegmann D, Ju C. (2006). Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology, 44, 1421–31.
   PubMed Web of Science ®Google Scholar
• Yuan QS, Zheng FL, Sun Y, Yu Y, Li Y. (2000). Rescue therapy with tacrolimus in renal graft patients with cyclosporine A-induced hepatotoxicity: a preliminary study. Transplant Proc, 32, 1694–5.
   PubMed Web of Science ®Google Scholar
• Zhang A, Sun H, Sun W, Ye Y, Wang X. (2013a). Proteomic identification network analysis of haptoglobin as a key regulator associated with liver fibrosis. Appl Biochem Biotechnol, 169, 832–46.
   PubMedGoogle Scholar
• Zhang J, Wang W, Yang F, Zhou X, Jin H, Yang PY. (2012). Comparative proteomic analysis of drug sodium iron chlorophyllin addition to Hep 3B cell line. Analyst, 137, 4287–94.
   PubMed Web of Science ®Google Scholar
• Zhang S, Liang R, Luo W, Liu C, Wu X, Gao Y, et al. (2013b). High susceptibility to liver injury in IL-27 p28 conditional knockout mice involves intrinsic interferon-gamma dysregulation of CD4 + T cells. Hepatology, 57, 1620–31.
   PubMedGoogle Scholar
• Zhang W, Zhang L, Chen YX, Xie YY, Zou YF, Zhang MJ, et al. (2014). Identification of nestin as a urinary biomarker for acute kidney injury. Am J Nephrol, 39, 110–21.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu F, Chen X, Zhu X, Uetrecht J. (2011). Involvement of the immune system in idiosyncratic drug reactions. Drug Metab Pharmacokinet, 26, 47–59.
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan E, Duan W, Huang M, Chen YZ. (2005). Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab Rev, 37, 41–213.
   PubMed Web of Science ®Google Scholar
• Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F. (2012a). Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int, 32, 500–9.
   PubMed Web of Science ®Google Scholar
• Zimmermann HW, Trautwein C, Tacke F. (2012b). Functional role of monocytes and macrophages for the inflammatory response in acute liver injury. Front Physiol, 3, 56.
   PubMed Web of Science ®Google Scholar